FOXP3 and cancer: According to the density and distribution of CD8+ T cells and FOXP3+ regulator T (Treg) cells etc, which determine the classification of “hot” versus “cold” tumors, the clinical outcome of various cancer patients can be predicted: “hot” tumors have potential sensitivity to immunotherapy (8).